Organon & Co. (NYSE:OGN) SVP Acquires $353,080.80 in Stock

Key Points

• SVP Lynette Holzbaur bought 26,448 shares of Organon at an average price of $13.35 on May 6 for a total of $353,080.80, boosting her stake to 52,851 shares — a 100.17% increase in ownership.
• Organon missed quarterly EPS ($0.71 vs. $0.83) with revenue down 3.5% year-over-year; the stock trades near $13.36 while analysts' consensus rating is "Reduce" with an average target of $11.40, and the company pays a $0.02 quarterly dividend (0.6% yield).

Organon & Co. (NYSE:OGN - Get Free Report) SVP Lynette Holzbaur purchased 26,448 shares of the stock in a transaction on Wednesday, May 6th. The stock was acquired at an average cost of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president owned 52,851 shares in the company, valued at approximately $705,560.85. This represents a 100.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Organon & Co. Price Performance

Shares of NYSE OGN traded down $0.06 during midday trading on Thursday, hitting $13.36. 3,102,525 shares of the company's stock were exchanged, compared to its average volume of 8,179,798. The company has a current ratio of 1.97, a quick ratio of 1.23 and a debt-to-equity ratio of 9.47. The business's fifty day moving average price is $7.90 and its two-hundred day moving average price is $7.79. The company has a market cap of $3.51 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 1.24 and a beta of 1.57. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.44.

Organon & Co. (NYSE:OGN - Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $0.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.83 by ($0.12). The company had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The company's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.02 earnings per share. As a group, research analysts forecast that Organon & Co. will post 3.23 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Monday, May 11th will be given a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a yield of 0.6%. Organon & Co.'s dividend payout ratio (DPR) is presently 8.60%.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on OGN shares. Wall Street Zen lowered Organon & Co. from a "buy" rating to a "hold" rating in a research report on Saturday, January 31st. Barclays upped their target price on Organon & Co. from $7.50 to $8.00 and gave the stock an "underweight" rating in a research note on Tuesday, February 24th. Zacks Research raised shares of Organon & Co. from a "strong sell" rating to a "hold" rating in a research note on Tuesday, April 14th. Piper Sandler raised shares of Organon & Co. from an "underweight" rating to a "neutral" rating and upped their price objective for the company from $5.00 to $14.00 in a research note on Tuesday, April 28th. Finally, BNP Paribas Exane reiterated a "neutral" rating and issued a $14.00 target price (up from $12.00) on shares of Organon & Co. in a research report on Wednesday, April 29th. Four equities research analysts have rated the stock with a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat.com, Organon & Co. has a consensus rating of "Reduce" and an average price target of $11.40.

Institutional Investors Weigh In On Organon & Co.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Amalgamated Bank raised its stake in shares of Organon & Co. by 1.9% during the third quarter. Amalgamated Bank now owns 79,805 shares of the company's stock valued at $852,000 after acquiring an additional 1,514 shares during the last quarter. State of Alaska Department of Revenue raised its position in Organon & Co. by 0.6% during the 4th quarter. State of Alaska Department of Revenue now owns 278,379 shares of the company's stock valued at $1,995,000 after purchasing an additional 1,570 shares during the last quarter. Integrated Wealth Concepts LLC lifted its holdings in Organon & Co. by 2.8% in the 3rd quarter. Integrated Wealth Concepts LLC now owns 58,648 shares of the company's stock worth $626,000 after buying an additional 1,594 shares during the period. Arizona State Retirement System grew its position in shares of Organon & Co. by 2.2% in the 3rd quarter. Arizona State Retirement System now owns 76,924 shares of the company's stock worth $822,000 after buying an additional 1,644 shares during the last quarter. Finally, Rothschild Investment LLC increased its stake in shares of Organon & Co. by 73.1% during the third quarter. Rothschild Investment LLC now owns 3,899 shares of the company's stock valued at $42,000 after buying an additional 1,646 shares during the period. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.